57% overturnedAppeal outcomes · Infused drugs

Denied IVIG: what independent reviewers actually decided

IVIG denials turn on two things at once — that the diagnosis is established, and that what should have been tried first was tried.

Intravenous immune globulin infused in an office, infusion suite or hospital outpatient department and billed under a product-specific supply code. Immunology, neurology and haematology indications dominate.

What the independent reviewers decided

57%

overturned by the independent reviewer

140

of 246 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny IVIG

  • The policy limits coverage to an enumerated list of indications and the requested one is not on it, or is on it only with conditions.
  • Laboratory confirmation the policy requires — immunoglobulin levels, specific antibody response, electrodiagnostic findings — is absent from the file.
  • A required prior therapy has not been documented as tried and failed.
  • Dosing, frequency or duration exceeds the policy's ceiling without a stated justification.

What actually carried the cases that won

Prior treatment led, but IVIG is one of the procedures where diagnostic confirmation did real work alongside it. These are indications where the diagnosis itself is often the contested question, and the overturned files tended to close that question first — the laboratory or electrodiagnostic evidence, then the therapy history — rather than arguing necessity on top of an unsettled diagnosis. Peer-reviewed literature and clinical guidelines were the reviewers' principal authorities.

What the record showedShare of overturned decisions
Prior treatment was documented62%
The condition was documented as chronic or long-standing45%
A published guideline supported the request42%
The diagnosis was confirmed36%
The severity or urgency was documented33%
Conservative treatment was documented as failed33%
The functional impact on the patient was documented29%
Objective findings were documented23%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

  • Peer-reviewed literature — in 47% of the overturned decisions
  • Clinical guidelines — in 11% of the overturned decisions
  • FDA labeling — in 9% of the overturned decisions
  • Standard of care — in 7% of the overturned decisions
  • Specialty-society criteria — in 6% of the overturned decisions

IVIG denials — frequently asked

Is a denied IVIG claim worth appealing?
57% of 246 California independent medical reviews of IVIG were overturned. That is a majority, but a narrower one than the infused-biologic group, and the corpus suggests why: IVIG appeals more often have to establish the diagnosis as well as the necessity.
What should the record establish first?
The diagnosis, on the evidence the policy names — immunoglobulin levels and specific antibody response for immunodeficiency, electrodiagnostic findings for the neurological indications. An appeal that argues necessity while the diagnostic basis is still open is answering the second question before the first.
Does the product matter?
It can. Several plans designate preferred immune globulin products and deny a non-preferred one on that basis alone. Where the denial is a product-preference denial rather than an indication denial, the appeal is about why this product for this patient — contraindication, intolerance, or a documented product-specific requirement.

Related guides

CO-50 — not medically necessaryDrug coverage and appealsMedical necessity appeal letters

Source

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →